Private Wealth Management Group’s Celldex Therapeutics CLDX Stock Holding History

Private Wealth Management Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04K	Hold	28	–	–	﹤0.01%	1297
2026 Q1	$889	Hold	28	–	–	﹤0.01%	1272
2025 Q4	$761	Hold	28	–	–	﹤0.01%	1319
2025 Q3	$725	Hold	28	–	–	﹤0.01%	1358
2025 Q2	$570	Sell	28 -98	-78%	-$1.91K	﹤0.01%	1403
2025 Q1	$2.29K	Buy	+126	New	+$2.81K	﹤0.01%	1013

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Wealth Management Group's CLDX Position: Q2 2026 in Review

Private Wealth Management Group held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 28 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

Private Wealth Management Group first reported a position in CLDX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.29K in Q1 2025. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Private Wealth Management Group held 28 shares of Celldex Therapeutics worth $1.04K as of Q2 2026.
Private Wealth Management Group left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #1297 holding.
Private Wealth Management Group first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 6 quarters since.
Private Wealth Management Group's Celldex Therapeutics position peaked at $2.29K in Q1 2025.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.